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INTRODUCTION
Tigecycline, the first member of the glycylcy-
clines, has been approved for complicated skin 
and soft tissue infections (cSSTIs) and compli-
cated intra-abdominal infections (cIAIs) (Euro-
pean Medicine Agency, 2014). Tigecycline has 
a wide range of activity against Gram-positive 
and Gram-negative bacteria, including anaer-
obes, has a wide volume of distribution and a 
peculiar mechanism of action, inhibiting bac-
terial protein synthesis by binding to the 30S 
ribosomal subunit with five times higher affin-
ity than the tetracyclines (Pankey, 2005; Greer, 
2006; Batthacharya et al., 2009). 
Notwithstanding the official indications, clini-
cal use of tigecycline has been heterogeneous, 
including pulmonary and bloodstream infec-
tions as well as infections by multi-drug re-
sistant (MDR) bacteria since patients do not 
fit into clinical protocols (Dryden, 2013; De 
Pascale et al., 2014). Confusion has been gen-
erated by its administration in official indica-
tions as well as in complicated respiratory or 
bloodstream infections, as a monotherapy or as 
a part of combination therapy, at the standard 
dosage of 50 mg twice daily or at high dosag-
es (HD) of 100 mg twice daily, in patients with 
community-acquired (CA) infections as well 
as health-care associated (HCA) or nosocomi-
al infections (HA). As a consequence, issues 
and warnings of increased mortality have been 
raised by meta-analyses calculated on hetero-
geneous patients with ventilator-associated 
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Tigecycline, the first member of the glycylcyclines, has been approved for complicated skin and soft tissue infections 
(cSSTIs) and complicated intra-abdominal infections (cIAIs). It has a wide range of activity against Gram-positive 
and Gram-negative bacteria, including anaerobes. Since its approval, the worldwide clinical use of tigecycline 
has been heterogeneous, either as a monotherapy or as a part of combination therapy, almost exclusively at the 
standard dosage, in patients with community-acquired (CA) infections as well as health-care associated (HCA) or 
nosocomial infections (HA), including infections caused by multidrug-resistant (MDR) bacteria. In recent years, 
issues and warnings of an increased mortality in these heterogeneous patients treated with tigecycline have been 
raised by meta-analyses and by regulatory agencies. 
Re-defining tigecycline therapy is a proposal, based on epidemiological, clinical, microbiological and pharma-
cological considerations, to distinguish patients who may be treated with monotherapy, according to the official 
indications and dosages, from those treated with combination treatment, mostly with high dosages in the setting 
of nosocomial IAIs, possibly caused by MDR bacteria or as a carbapenem-sparing strategy. Whilst available clinical 
data and guidelines suggest caution with monotherapy in severe infections, experience worldwide indicates that 
combination treatment with high-dosage tigecycline is increasingly used.
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pneumonia (VAP), hospital-acquired pneumo-
nia (HAP), diabetic foot infections, infections 
by MDR bacteria and shock not better defined 
(FDA, 2010; European Medicine Agency, 2011; 
European Medicine Agency, 2014).
In Europe, the benefit/risk evaluation of the 
European Medicines Agency’s (EMA) Com-
mittee stated that the benefits of tigecycline 
treatment continue to outweigh its risks, but 
recommended that the product information be 
changed to ensure appropriate use by making 
prescribers aware of an increased mortality in 
clinical studies (Dryden, 2013; European Med-
icine Agency, 2014). Subsequently, the FDA 
conducted another meta-analysis in September 
2013 with 10 clinical trials including only the 
approved use of tigecycline, which showed an 
increased mortality with an adjusted risk dif-
ference of 0.6% (FDA, 2013; Dixit et al., 2014). 
A boxed warning was issued for the antibiotic, 
cautioning administration either for approved 
and unapproved indications (FDA, 2013). In a 
critical safety review the increased mortality 
with tigecycline was not well understood and 
the authors reviewed the side-effects and drug 
interactions of tigecycline (Kaewpoowat et al., 
2014).
Therefore, a basic question concerns the future 
of tigecycline (Bassetti et al., 2014). From this 
viewpoint, we propose some considerations 
to re-define the clinical use of tigecycline as 
monotherapy or combination treatment based 
on epidemiological, microbiological, pharma-
cological and clinical considerations.
MICROBIOLOGICAL ACTIVITY 
The spectrum of activity of tigecycline encom-
passes the spectrum of community and noso-
comial infections, including a broad range of 
Gram-positive and Gram-negative bacteria as 
well as anaerobes, ‘atypical’ bacteria (Myco-
plasma, Legionella and Chlamydia species) and 
many species of multidrug-resistant bacteria 
such as methicillin-resistant Staphylococci, 
vancomycin-resistant Enterococci, MDR Acine-
tobacter baumannii and Klebsiella pneumoniae 
carbapenemase producing K. pneumoniae (KPC-
Kp). Tigecycline is not active against Pseudo-
monas aeruginosa and Proteus spp., Morganella 
and Providencia species (Bradford et al., 2005; 
Pankey, 2005; Greer, 2006; Bhattacharya et al., 
2009). Tigecycline has a low minimum inhib-
itory concentration against C. difficile in vitro 
and may be able to alter the pathogenesis of the 
disease in a mouse model of C. difficile infection 
(Theriot et al., 2014). The microbiological activ-
ity is coupled with a novel mechanism of action 
that does not stimulate any induction of resis-
tance to other classes of antibiotics (European 
Medicines Agency, 2014). This feature has been 
adapted to “carbapenem-sparing” treatment 
strategies where carbapenemase-producing 
bacteria such as KPC-Kp are an issue (Sbrana 
et al., 2013).
The carbapenem-sparing strategy is also useful 
in reducing the selective pressure of carbap-
enems in hospitals with a high prevalence of 
ESBL production amongst Gram-negative bac-
teria (Garau, 2008). As far as tigecycline is con-
cerned, HD was mostly given at 100 mg twice 
daily and interestingly, there are data showing 
in vivo bactericidal activity of HD tigecycline 
against ESBL-producing K. pneumoniae (Mi-
chail et al., 2013; De Pascale et al., 2014).
Pharmacokinetics and pharmacodynamics
The safety and tolerability of tigecycline admin-
istered as single or multiple doses or at various 
infusion rates were explored in three phase 1, 
randomized, double-blind, placebo-controlled 
studies in healthy subjects (Muralidharan et al., 
2005). No serious adverse events were reported 
in any of the three studies. The most common 
dose-related adverse events reported were nau-
sea and vomiting, which are common to the 
tetracycline class of antibiotics. At the higher 
doses (200 and 300 mg), prolonging the infu-
sion duration to 4 hours did not improve the 
incidence or severity of nausea, indicating that 
the nausea is not directly related to the Cmax of 
the drug in serum. Also, the nausea and vomit-
ing diminished when the 200 mg dose was ad-
ministered to fed subjects rather than to those 
fasting. However, there are multiple reports of 
safety of HD tigecycline with appropriate dilu-
tions and slow infusion, especially in the criti-
cal care setting (De Pascale et al., 2014). Recent 
data show that tigecycline was associated with 
decreased fibrinogen levels, which was revers-
ible after cessation of treatment and the HD 
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group of patients had greater decreases than 
those given the normal dose, without any effect 
of age (Zhang et al., 2014).
Given at the standard approved dose of 100 mg 
followed by 50 mg every twelve hours, tigecy-
cline has relatively low mean steady-state se-
rum concentrations of 0.403 mg/L and 0.633 
mg/L in subjects with complicated skin and soft 
tissues infection (cSSTI) included in phase 2 
and 3 studies, respectively (Postier et al., 2004). 
The half-life (t1/2) in humans is relatively long, 
ranging from 37 to 67 hours in healthy volun-
teers, probably because of its large volume of 
distribution (Muralidharan et al., 2005).
The pharmacokinetics of tigecycline was re-
cently evaluated in obese versus normal weight 
healthy adult volunteers after a single intrave-
nous dose of 100 mg administered in 30 min-
utes. The serum concentration-time profiles and 
exposures were similar in the obese and normal 
weight adults, with a mean urine recovery of 
15.8% and 13.4%, respectively (Pai, 2014). The 
median (range) AUC0-∞ was 8.19 (6.12, 11.2) and 
7.50 (6.78, 9.13) mg*h/L in the obese and nor-
mal weight groups, respectively. The clearance 
of tigecycline was not related to the total body 
weight (TBW). Tigecycline distributes widely 
into various fluids and tissues, such as lungs, 
skin, liver, heart, and bone (Table 1).
Tigecycline concentrations were measured in 
patients four hours after the administration of 
a single 100 mg dose (Rodvold et al., 2006). The 
ratio of tissue:serum was 38-fold in the gall-
bladder, 8.6-fold in the lungs, 2.1-fold in the co-
lon, 0.35-fold in the bone, and 0.58-fold in the 
synovial fluid. 
Tissue distribution in bone was recently reas-
sessed. Serum and bone AUC for the given dose 
interval (AUCτ) values were 2,402 ng h/mL and 
11,465 ng h/g, and maximum concentration 
(Cmax) values were 974 ng/mL and 2,262 ng/g, 
respectively. The bone to serum ratio calculat-
ed using the AUCτ values was 4.77, confirming 
tigecycline penetration into bone (Bhattacha-
rya et al., 2014).
Tigecycline had a 74% (mean) penetration into 
the blister fluid (relative to serum) in a cantha-
ridin ointment-induced blister model in healthy 
subjects receiving seven standard doses of tige-
cycline (Sun et al., 2005). However, higher con-
centrations of tigecycline in skin and soft tissue 
than in the serum at the same time point after 
1 to 6 days of standard treatment were recent-
ly found. The mean tissue:serum ratios at the 
three study time periods were 3.8 (range 0.7-
5.5), 5.2 (range 0.8-7.1) and 2.8 (range 0.8-8.8) 
(Stein et al., 2011).
Tigecycline has a moderate degree of plasma 
protein binding (approximately 68%). Repeat-
ed daily administration results in minimal ac-
cumulation. As the predominant component 
in serum, urine, and faeces is unchanged, tige-
cycline drug metabolism is limited. Glucuro-
nidation and amide hydrolysis, followed by 
TABLE 1 - Concentrations of tigecycline in serum, tissues and body fluids after a 100 mg dose of tigecycline.
Site and Sampling Time Serum, mg/L* Site, mg/L or mg/kg* Reference
Bone (2-12 hours) 0.974 0.898 (0.26-2.26) Bhattacharya et al., 2014.
Bile
12 hours
24 hours
0.093±0.024
0.066±0.016
148.1±155.4
55.8±50.5
Rodvold, et al., 2009.
Gallbladder
12 hours
24 hours
0.093±0.024
0.066±0.016
7.29±7.88
2.52±3.19
Colon
12 hours
24 hours
0.139±0.037
0.078±0.029
1.30±2.43
0.575±0.485
Lung
12 hours
24 hours
0.083±0.007
0.088±0.103
0.380±0.260
0.401±0.222
Skin
3 hours
9 hours
0.56±0.25
0.26±0.12
2.128 (0.39-3.08)
0.728 (0.20-2.28)
Stein et al., 2011
*Data are expressed as mean ± standard deviation or (range).
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N-acetylation, are the main metabolic pathways 
in humans, and the predominant mode of ex-
cretion is via the biliary/faecal route (Zhanel et 
al., 2006). 
Tigecycline has been the subject of several phar-
macokinetic-pharmacodynamic (PK/PD) analy-
ses, using data from animal infection models 
as well as data from clinical trials of patients 
suffering from cSSSI infections or those with 
cIAIs (Van Ogtrop et al., 2000; Meagher et al., 
2007; Passarell et al., 2008). These analyses in-
dicate that the ratio AUC:MIC for serum tigecy-
cline concentration is a predictor of therapeutic 
response.
Particularly in patients with cSSTI, the classifi-
cation-and-regression-tree (CART) analy-
sis-identified AUC24/MIC breakpoint of 17.9 
was a statistically significant predictor of clini-
cal outcome (p=0.0376) (Meagher et al., 2007). 
When exposure-response analyses were per-
formed in cIAIs, CART analyses identified a 
significant AUC:MIC breakpoint of 6.96 for mi-
crobiological and clinical responses (p values of 
0.0004 and 0.399, respectively) (Passarell et al., 
2008). More recently, the influence of a num-
ber of factors, including adequate antibacteri-
al therapy, on the clinical response of patients 
with IAIs treated with tigecycline at standard 
dose was demonstrated. Of the six significant 
factors identified, an AUC:MIC ratio of >3.1 
was found to be the most important factor in 
determining outcome. Most importantly to 
consider, this was the only factor that is amena-
ble to intervention by the clinician.
So far, pharmacological parameters may ex-
plain why in one phase III cSSTIs study there 
were lower rates of clinical cure and microbi-
ological eradication in the microbiologically 
evaluable population at the test-of-cure (Beedt 
et al., 2005).
An in vitro pharmacodynamic model simulat-
ing exposures likely to occur in the epithelial 
lining fluid of patients with pneumonia showed 
that tigecycline had little activity against KPC-
Kp isolates when simulated alone or in combi-
nation with rifampin. In contrast, a statistical-
ly significant synergistic antimicrobial effect 
was noted when tigecycline and meropenem 
were simulated together for KPC-Kp isolates 
with MICs of ≤2 and ≤16 µg/ml, respectively 
(Wiskirchen et al., 2011). 
TIGECYCLINE IN CLINICAL PRACTICE
Tigecycline is approved in Europe for the treat-
ment of cSSTIs and cIAIs with supporting 
studies of non-inferiority (Table 2). After its in-
troduction in clinical practice, the novel mech-
anism of action and the activity against MDR 
bacteria were mostly intended as a new weap-
on, as empiric and targeted treatment, against 
difficult-to-treat infections. 
Numerous papers were published on the micro-
biology and treatment of critically ill patients 
as well as patients with cancer or multiple or-
gan failures, generating confusion with the 
official indications (Table 3). A clinical puzzle 
was built, with pieces made from epidemio-
logical settings, monotherapy or combination 
therapies, primary or salvage treatment with 
standard dosage or in a variety of HD syn-
dromes and critical illnesses. In a recent pa-
per by Montravers et al. on real-life experience 
with tigecycline in 254 patients with cSSTI in 
four countries, there were 112 (44.4%) first-
line treatments and monotherapy was used in 
181 patients (71.8%) (Montravers et al., 2013). 
When used as monotherapy, treatment success 
was reported in 86.7% of cases, and a less favor-
able clinical outcome amongst patients who re-
ceived combination therapy could be explained 
by a potential bias within the groups (Montra-
vers et al., 2013).
The first experience outside of the official in-
dications in surgical critically ill patients with 
severe sepsis and septic shock was reported in 
a surgical ICU by Swoboda et al. (2008). The 
authors retrospectively analysed 70 patients 
(cancer: 51%; renal replacement therapy: 57%; 
mean APACHE II score at admission: 27; in-
tra-abdominal infection: 50%). As many as 76% 
of patients received tigecycline in combination, 
mainly with a carbapenem, and 64% were treat-
ed as a second line. Overall, tigecycline resulted 
in markedly reduced mortality (Swoboda et al., 
2008).
In a prospective observational study in 26 
French ICUs, a total of 156 patients with sever-
al syndromes were treated with tigecycline and 
53% had a SOFA score ≥7 and 93% had received 
other anti-infective agents (Montravers et al., 
2014). Tigecyline was given at standard dosage 
in 97% of patients and in combination in 65% 
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of them; the global success rate was 60% at the 
end of treatment and the survival rate at day 28 
was 85% in the whole cohort and significantly 
higher in the less severely ill patients. 
There also are numerous papers reporting tige-
cycline administration and success or failure 
in a variety of diseases, including VAP and 
complicated nosocomial intra-abdominal in-
fections (IAIs) caused by MDR Gram-negative 
bacteria including Enterobacteriaceae, P. aeru-
ginosa, Acinetobacter spp. and S. maltophilia 
(Table 3). 
The main result was that confusion was gen-
erated by mixing different syndromes, empir-
ic and targeted treatment, different severity of 
diseases, monotherapy and combination treat-
ment. Eventually, this substantial heterogeneity 
was taken as a substrate for meta-analysis.
META-ANALYSES OF EFFICACY 
AND SAFETY
Meta-analyses are powerful tools to solve a clin-
ical problem, but there is no universal agree-
ment on their theoretical validity, practical ap-
plication or interpretation (Piantadosi, 2000). 
Critical points are represented by the baseline 
heterogeneity of included studies, with conclu-
sions that may be weak or strong depending 
on these studies, by the definition of “treat-
ment”, and the methods used to synthetize the 
TABLE 2 - Pivotal clinical studies with tigecycline in complicated skin and skin structure infection (cSSSI) and 
complicated intra-abdominal infections (cIAIs).
Author Type of infection No. 
patients
Drug regimen Outcome
Tigecycline Comparator
Ellis-Grosse 
et al., 2005
cSSSI (polymicrobial 
etiology, need for 
surgical intervention, 
suspected or confirmed 
deep soft tissue 
involvement and/or 
comorbidities)
1116 100 mg, followed 
by 50 mg IV twice 
daily. (N = 556)
Vancomycin 
(1 g IV twice 
daily) plus 
aztreonam 
(2 g IV twice 
daily). 
(N = 550)
Clinical responses 
to tigecycline and 
comparators at test-
of-cure were similar 
(86.5% versus 88.6% 
in clinically evaluable 
population) as well 
as overall eradication 
rate of MRSA 
(78.1% and 75.8% 
respectively) and 
adverse events
Babinchak 
et al., 2005
cIAI (requiring a 
surgical procedure for 
an intra-abdominal 
abscess or peritonitis 
associated with an 
abscess or perforation)
1642 100 mg, followed 
by 50 mg IV every 
12 h. (N = 817)
Imipenem-
cilastatin 
500/500 mg 
IV every 6 h. 
(N = 821)
Small proportion 
of patients with 
APACHE II >15 (22 
[3.5%] tigecycline vs. 
13 [2.1%] imipenem/
cilastatin). Clinical 
cure and eradication 
rates in the evaluable 
population were 
similar in the two 
groups. 9/117 E. 
coli were found to 
produce ESBL, with 
tigecycline MIC 
range equivalent to 
non-ESBL producer 
strains. 7 (78%) of 9 
patients with ESBL-
producing E. coli 
achieved clinical cure 
or eradication after 
tigecycline.
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TABLE 3 - Clinical heterogeneity of real-life treatment with tigecycline.
Study, 
(no. patients)
Type of infections, 
(no. patients)
Pathogens Treatments 
[M=monotherapy; 
C=combination; 
(no. pts)]
Dosage 
(S=standard 
H=high)
Outcomes
Scahfer et al., 
2007. 
Retrospective, 
(25).
VAP (22, 3 with BSI), 
BSI (3) 60% surgical
MDRAB 30% 
TG-IR, 
5% TG-R
M (5)
S
Resolution 84%; microbial 
eradication 80%C (20)
Swoboda et al., 
2008 
Retrospective, 
(70).
cIAI (40, 10 + HAP), 
HAP (12) BSI (2), 
UTI (2), cSSTI (6), 
bone and joint (1), 
unknown (2)
Gram-positive (58) 
S. maltophilia (13), 
A. baumannii (1), 
E. cloacae (1), 
B. cepacia (1)
M (1)
S
30% ICU mortality (Outcomes 
of Gram-negative infections 
cannot be separated)
C(44)
Vasilev et al., 
2008
Prospective, 
open non 
comparative 
phase III, (34).
cSSTI (24) cIAI (5), 
HAP (5), CAP (1), 
BSI (1)
A. baumannii (17), K. 
pneumoniae (6), E. 
coli (9), Enterobacter 
spp., (4)
M(34)
S
Clinical cure 72.2%; 
microbiological cure 66.7%.  
A. baumannii infections clinical 
cure 82.4%; microbiological cure 
64.7%
Anthony et al., 
2008
Retrospective, 
(18; 19 
infections).
VAP (6, 3 with 
empyema), HAP (2), 
BSI (1), UTI (2), 
tracheobronchitis (2), 
mediastinitis with 
secondary BSI (1), 
other (4)
10 MDRAB; 
44% TG-S, 
56% TG-IR
M (9)
S
Positive clinical response 50%, 
uncertain 10%, survival 60%; all 
deaths related to infection with 
TG-IR pathogens; microbiological 
response in 75%; emergence of 
resistance in 1 patient
C (9)
6 K. pneumoniae 
(4 ESBL+, 
1 ESBL + KPC-Kp), 
2 E. cloacae, 
1 E. coli (KPC-Kp)
Gallagher 
et al., 2008.
Retrospective, 
(28; 29 
infections).
HAP (17, 2 with BSI), 
BSI (4), UTI (3), 
IAI (1), wound 
infection (3), 
tracheobronchitis (1)
29 A. baumannii M (12)
NA
28% positive clinical outcome; 44 
% microbiological eradication; 
62% negative outcome, 68% 
mortality (19 patients, attributable 
in 15/19 patients); Clinical 
and microbiological outcomes 
associated significantly
C (17)
Curcio et al., 
2009.
Prospective 
noncomparative, 
(75).
VAP (6 with BSI) A. baumannii. 44/73 
IMP-S, 29/73 only 
COL-S/TG-S
22 patients no 
other antibiotics 
or 48 h
NA
69.9% clinical success. Success in 
2/6 bacteraemic infections. 33% 
crude mortality
(37% concomitant 
anti-pseudomonal 
treatment)
Gordon et al., 
2009.
Retrospective, 
(34).
IAI (6, 1 + HAP, 3 + 
VAP), HAP (8), BSI (9, 
7 + other), bone and 
joint and cSSTI (10), 
intracranial (1)
A. baumannii (19), 
mixed with A. 
baumannii (15)
M (12)
S
68% positive clinical outcome; 
29.4% microbiological 
eradication; 56% positive results 
in bacteraemia. Mortality: 
overall 41%, attributable 26.4%; 
3 breakthrough BSI (1 with 
resistance)
C (22)
Poulakou 
et al.,2009
Retrospective, 
(45).
VAP/HCAP (21, 2 with 
BSI), BSI (10), SI (14)
A. baumannii (26 
MDR, 2 PDR, all 
CRB-R) TG MIC 1–8 
mg/L, K. pneumoniae 
(20 MDR, 3 PDR), 
TG MIC 1–3 mg/L, 
Enterobacteriaceae 
(3)
M (22)
S
Clinical success: VAP 90%, BSI 
80%, SI 64.3%, monotherapy group 
81.8%, combined therapy group 
78.3 %, 4 breakthrough Gram-
negative BSI (1 with emergence 
of resistance), 10 superinfections 
from microorganisms inherently 
resistant to TG
C (23)
→
Re-defining tigecycline therapy 127
Study, 
(no. patients)
Type of infections, 
(no. patients)
Pathogens Treatments 
[M=monotherapy; 
C=combination; 
(no. pts)]
Dosage 
(S=standard 
H=high)
Outcomes
Jamal et al.,
2009
Retrospective, 
(24).
HAP/VAP (5), BSI (9), 
CR-BSI (1), UTI (2), 
cSSSI (1)
MDRAB [1st 
outbreak isolates 
meropenem-
susceptible (MIC 
2–3 mg/L)]. TG MIC 
0.75–2 mg/L
First outbreak: 
start with 
combination, 
switch to MER S
First outbreak 6 patients, 50% 
mortality, time to pathogen 
clearance 8.3 days;
Second outbreak: 12 patients, 8.6% 
mortality, time to clearance 2.8 
days; Third outbreak: 6 patients 0% 
mortality; time to clearance 3.1 days
Second and third 
outbreaks: TG 
monotherapy
Freire et al., 
2010
Phase 3, 
multicentre, 
randomized, 
double-blind 
study, (945).
Non-VAP (27), VAP (40) 67 A. baumannii 
(MIC range 0.12–8 
mg/L)
TG plus optional 
adjunctive therapy 
with CAZ or IMP 
and optional 
adjunctive therapy 
with VAN
S
Cure rates 67.9% for TG and 78.2% 
for IMP (CE patients) and 62.7% 
and 67.6% (c-mITT patients), 
respectively; Overall mortality: TG 
14.1%, IMP 12.2% (more deaths 
occurred in VAP treated with TG 
(NS). Overall TG was noninferior to 
IMP for the c-mITT but not the CE 
population; this difference appears 
to have been driven by results 
in VAP patients. A. baumannii 
infections, clinical response: non-
VAP TG 90% IMP 70.6%; VAP TG 
57.1% IMP 94.7%. Eradication of A. 
baumannii at test of cure: 71%
An AMG was 
permitted for 
double coverage 
against P. 
aeruginosa
Metan et al., 
2010.
Retrospective, 
(21).
SI, VAP 18 A. baumannii 
infections, 3 mixed
M (7)
NA
Clinical success 80.95%; 14-day 
attributable mortality 9.5%; Crude 
30-day mortality 19.1%: SI better 
outcomes
C (14)
Kuo et al., 2011
Retrospective, 
(66).
Group 1, FDA-approved 
indications (12); Group 
2, HAP (38); Group 3, 
UTI (4), osteomyelitis 
(4), CRBSI (3), BSI (3), 
57.6% ICU patients
25 MDRAB. K. 
pneumoniae, 
Citrobacter spp., 
Serratia spp., 
S. maltophilia. 
P. aeruginosa, 
Providencia stuartii
Combinations 
(65,1%)
S
Positive clinical outcome 30.3%; 
higher clinical success rate for 
group 1 than 2 (higher disease 
severity and risk factors in 
group 2); MDRAB infections: 
positive clinical outcome 12%; 
microbiological eradication in only 
1 patient; 18 persistent infections 
and four superinfections. Hospital 
mortality 68%. VAP by MDRAB: 
success rate 5.6%
MDRAB: 10 TG 
monotherapy, 
15 combination 
therapy
Ye et al., 2011
Retrospective, 
(112).
116 pneumonia 
involving A. baumannii; 
10 with bacteraemia
Monomicrobial 
A. baumannii 
pneumonia in 26.7%; 
polymicrobial 73.3% 
(30.2% with gram(+) 
and 56.7% with 
gram(-)
Combinations 
(62.1%)
S
Monomicrobial MDRAB 
pneumonia: significantly lower 
clinical resolution rate than 
polymicrobial (45.2 vs. 65.9%; no 
difference with monotherapy). 
Among 6 episodes with MDR 
bacteraemia only those with 
tigecycline MIC B 1 mg/L survived. 
30-day mortality 36.2%
Monomicrobial 
(31): 9 TG 
monotherapy and 
22 combination 
therapy
Polymicrobial 
(85): 35 TG 
monotherapy and 
50 combination 
therapy
Guner et al., 
2011
Retrospective, 
(33).
VAP (19), BSI (11), 
SSI (2)
MDRAB or 
polymicrobial 
infection involving 
MDRAB
M (2)
S
Positive clinical outcome 63.63%; 
30-day overall mortality 57.6%; 
Attributable mortality 24.2%; 
Superinfections 39.3%
C (31)
→
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Study, 
(no. patients)
Type of infections, 
(no. patients)
Pathogens Treatments 
[M=monotherapy; 
C=combination; 
(no. pts)]
Dosage 
(S=standard 
H=high)
Outcomes
Ku et al., 2012
Retrospective, 
(106).
CR-BSI (9), HAP/VAP 
(50), UTI (14), SSTI 
(22)
82 A. baumannii, 
12 CRE, 12 mixed 
(82% isolates non 
susceptible to TG)
M (16)
S
Patients colistin COL alone o + 
TG: more likely to die than only 
TG (37% vs 0%); Colistine: higher 
severity of acute illness and 
delays in initiation of effective 
antimicrobial therapy
Colistine 
monotherapy 71
C (19)
Moon et al., 2012
Retrospective, 
(108).
HAP (44), SSI (22), cIAI 
(18), BSI (5), non-ICU 
population
A. baumannii 50.3%, 
S. aureus 10.3%, 
K. pneumoniae 7.9%, 
Enterococcus spp. 
6.7%, E. coli 5.5%, 
P. Aeruginosa 4.9%
M (71)
NA
Overall 30-day mortality 52.9%;30-
day mortality of HAP 60.5%; 30-
day mortality of Acinetobacter spp. 
infection 59.4 %; Superinfection: 
29.6% (mostly P. aeruginosa)
C (27)
Kim et al., 2013
Retrospective, 
(9).
BSI 9 A. baumannii CRB-R 
and COL-S, TG-S
M (1)
S
Attributable mortality 55.5%; All-
cause hospital mortality 66.7%C (8)
Lee et al., 2013
Retrospective, 
(386).
HAIs MDRAB TG 266 patients 
(108 monotherapy, 
158 combinations)
S
TG vs non-TG groups; not 
significantly different number of 
infection-related deaths, length of 
hospital stay, or length of ICU stay 
and survival rates. Unfavourable 
outcomes significantly lower in 
the TG group than in the non-TG 
group (30.8% vs 50%). The most 
significant predictors of favourable 
outcomes: TG treatment and 
microbial eradication
non-TG 120 
patients
Ramirez et al., 
2013
Phase II study 
high doses TG 
in combination 
(105).
HAP/VAP 8 A. baumannii, 15 
Enterobacteriaceae, 3 
Haemophilus spp., 23 
S. aureus
C (105)
H
Clinical cure with TG 200 mg/day 
(85.0%) was numerically higher 
than with tigecycline 150 mg/day 
(69.6%) and imipenem (75.0%)
Bassetti et al., 
2013.
Observational 
multicentre 
registry (1,782).
cSSTI (254), cIAI 
(785), pneumonia, BSI, 
sepsis, ICU admission 
heterogeneous
At least 1 resistant 
pathogen: cSSTI 
30.5% cIAI 17.5%
M (50)
S
Clinical response rates with TG 
alone or in combination: cSSTIs 
79.6% and cIAIs 77.4%; All-cause 
mortality: cSSTI 9.4%, cIAI 18.7%
Combinations: 
175 TG-based
Chuang et al., 
2014
Retrospective, 
(294).
HAP/VAP MDRAB Combinations: 
17.41 TG-based, 
119 colistin-based S
Significantly higher mortality rate in 
the TG-based group (60.7%) vs. the 
COL group (44%); Post hoc analysis: 
mortality difference in cases with 
higher tigecycline MIC (2 lg/mL)
Montravers 
et al., 2014. 
Prospective 
observational 
multicentre, 
(156).
IAI (56%), cSSSI 
(19%), other (25%), 
bacteraemia in 12% 
Hospital-acquired 
(89%), ICU population;
Gram(+) 41.2%; 
Gram (-) 47.2%; 
Mixed 18.6%
C (65%)
S
Global success rate 60% (end of 
treatment; significantly higher with 
treatment duration more than 9 
days (76% vs. 47%) and in patients 
with BMI B 35 kg/m2 (56 % vs 13 
%); Survival rate at day 28, 85% 
(significantly higher in the less 
severely ill patients)
MDRAB multidrug-resistant Acinetobacter baumannii, VAP ventilator-associated pneumonia, CAP community-acquired pneumonia, HCAP he-
althcare-associated pneumonia, HAP hospital-acquired pneumonia, UTI urinary tract infection, BSI bloodstream infection, CR-BSI catheter-related 
BSI, cIAI complicated intra-abdominal infection, cSSTI complicated skin and soft tissue infection, SI surgical infection, MDR multidrug resistant, 
PDR pandrug resistant, MIC minimal inhibitory concentration, XDRAB extensively drug resistant A. baumannii, TG tigecycline, CRE carbapenem-
resistant, ESBL extended spectrum beta-lactamase, KPC-Kp carbapenemase-producing Klebsiella pneumoniae, NS non-statistically significant.
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results, suggesting caution and experience for 
the applied methods and reporting (Piantadosi, 
2000). The meta-analyses published on tigecy-
cline included patients with infectious diseas-
es other than cSSTIs and cIAIs, treated with 
monotherapy or combination therapy, inside 
and outside the ICU, with empiric and targeted 
treatment, including bloodstream infections, 
HAP and VAP. 
All the meta-analyses, summarized in Table 4, 
concluded that tigecycline should be used with 
caution or that it should be reserved as a last 
resort in combination with other antimicrobial 
drugs. These simple recommendations did not 
TABLE 4 - Summary of meta-analyses of tigecycline treatment.
Study Aim of the study N. trials/patients Type of infections Conclusions
Cai et al., 
2011.
Efficacy and 
safety of 
tigecycline 
and empirical 
antibiotic 
regimens in 
cSSSIs, cIAIs and 
other infections 
caused by MRSA 
or VRE
8 randomized 
clinical trials, 
4,651 patients
cSSIs, cIAIs, 
Commmity 
acquired 
pneumonia 
(CAP), MRSA or 
VRE infections
Tigecycline monotherapy: similar clinical 
and microbiological success rates, but 
incidence of adverse events significantly 
higher than comparator. No significant 
difference for all-cause mortality 
and drug-related mortality. Author 
conclusions: tigecycline monotherapy is 
as effective as comparison; however, due 
to high risk for mortality, adverse effects 
and emergence of resistant isolates, 
prudence is required
Tasina 
et al., 
2011
Efficacy of 
tigecycline for the 
treatment of adult 
patients with 
serious bacterial 
infection
14 published 
(N = 10 and 
unpublished 
(N = 4) 
multicentre 
randomised 
trials, ≈ 7,400 
patients,
cSSIs, cIAIs, 
CAP, MRSA or 
VRE infections
Tigecycline efficacy lower than that 
of comparators (small heterogeneity 
between studies) but the difference 
was not significant. Treatment efficacy 
was not significant for microbiological 
mITT and microbiologically assessable 
populations. Adverse events more 
frequent in the tigecycline group. All-
cause mortality was higher for group 
than comparators (difference not 
significant).
Yahav 
et al.,
2011
Comparison 
of tigecycline 
with any other 
antibiotic 
regimen for the 
treatment of any 
infection
15 clinical trials, 
7654 patients
cSSIs, cIAIs, 
CAP, Hospital 
acquired 
pneumonia 
(HAP), MRSA or 
VRE infections, 
diabetic foot 
infections ± 
osteomyelitis
Overall mortality: higher with tigecycline; 
clinical failure: significantly higher with 
tigecycline; microbiological failure non-
statistically significant higher. Authors 
statement: due to the increased mortality, 
probably explained by decreased clinical 
and microbiological efficacy, tigecycline 
monotherapy should be avoid for severe 
infections and reserved as a last-resort 
drug.
Prasad 
et al.,
2012
Comparison 
of tigecycline 
with any other 
antibiotic 
regimen for the 
treatment of any 
infection
13 RCT, 
7434 patients
cSSSIs, cIAIs, 
CAP,HAP,MRSA, 
VRE, diabetic 
foot infections
Mortality: Tigecycline versus comparator 
antibiotics was associated with a 0.7% 
absolute or 30% relative increase in 
mortality rates (RR, 1.30; 95% CI, 
1.02–1.65; p = .04); Non-cure rates: a 
significant 2.9% absolute or 12% relative 
increase (RR, 1.12; 95% CI, 1.02-1.23; 
p= .02). Subgroup analysis for type of 
infection: in each type but CAP the non-
cure rate was numerically increased with 
tigecycline.
*McGovern et al. pointed out that tigecycline has not been systematically studied and is not indicated in the treatment of septic shock, prima-
ry bacteraemia, and urinary tract infection; a clinical trial of tigecycline use in hospital-acquired pneumonia (HAP) failed to meet its primary 
endpoint and a phase II trial studying two higher doses of tigecycline in this indication was recently terminated due to enrollment difficulties; 
several trials were not identified and were not included in the analysis.69
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take into account the complex system of inter-
actions of drug(s)-patient(s)-bacteria. Clearly, 
one antimicrobial could be less effective than 
another if a poor clinical outcome may be pre-
dicted or if it was not properly dosed; it may 
be less effective also because it does not reach 
adequate levels at the site of action, as occurs 
in critically ill patients when altered patho-
physiological conditions increase the volume 
of distribution or clearance. Adequate dosing is 
necessary in such different pathophysiological 
situations.
In almost all studies included in the meta-anal-
yses, tigecycline was used at the fixed standard 
dose while the doses of the comparators were 
correctly adjusted on the basis of weight and 
creatinine clearance or on the basis of other 
clinical evaluations (Babinchak et al., 2005; Ta-
naseanu et al., 2008; Chen et al., 2010; Freire et 
al., 2010).
In particular, the clinical assessment and PK/PD 
analysis was evaluated in the study of Freire et 
al. (2010) where the efficacy and safety of tige-
cycline at the usual fixed dosing regimen were 
compared to imipenem/cilastatin at 500 mg to 
1 g intravenously every 8 hours on the basis of 
clinical judgment, in patients with HA pneu-
monia. A total of 123 patients died during the 
study; 66/467 (14.1%) in the tigecycline group 
and 57/467 (12.2%) in the imipenem/cilastatin 
group. However, a subanalysis revealed that in 
non-VAP patients, the mortality was the same 
in both regimens [41/336 (12.2%) in the tigecy-
cline group and 43/345 (12.5%) in the imipen-
em/cilastatin group], whereas the mortality in 
VAP patients was 25/131 (19.1%) and 15/122 
(12.3%) in the tigecycline and imipenem/cilas-
tatin groups, respectively. The analysis demon-
strated an increased mortality with tigecycline 
versus comparators in VAP patients. But why 
were the results different when excluding pa-
tients with VAP?
We should answer with data from the PK/PD 
analysis of tigecycline: the mean AUC0–12 were 
2.726 and 3.198 mg*h/L (P<0.041) in VAP and 
non-VAP patients, respectively. The clearance 
was also faster in VAP patients (23.3 L/h) com-
pared with non-VAP patients (20.7 L/h). Con-
sequently the median AUC0–24/MIC observed in 
VAP patients was 60% lower (P<0.002) than 
the value observed in non-VAP patients (1.730 
vs 4.389). Moreover, the weight of the patients 
enrolled in this study was significantly higher 
in the group treated with tigecycline compared 
to the group treated with imipenem-cilastatin 
(Freire et al., 2010). The conclusion is that in 
the study by Freire et al. the lower efficacy and 
the consequent higher mortality can potential-
ly be explained by the lower drug exposure due 
to physiological changes that occur in patients 
with VAP (Freire et al., 2010). The lesson we 
have learned in the past twenty years is that 
in critically ill patients, the dose should be 
adjusted on the basis of pathophysiological 
changes.
Bhavnani et al. evaluated the impact of differ-
ent factors on the probability of clinical re-
sponse in tigecycline-treated patients with IAIs, 
using phase 2 and 3 clinical data (Bhavnani et 
al., 2010). A final multivariable logistic regres-
sion model based on 123 patients demonstrated 
six factors to be predictive of clinical success: a 
weight <94 kg, the absence of P. aeruginosa in 
baseline cultures, an APACHE II score of <13, 
non-Hispanic race, complicated appendicitis 
or cholecystitis and an AUC:MIC ratio of >3.1. 
These findings demonstrated the impact of indi-
vidual and multiple factors on clinical response 
in the context of drug exposure (Bhavnani et al., 
2010). 
As far as pharmacokinetics and pharmacody-
namics is concerned, in his comment on the 
meta-analysis Scaglione (2011) stated that 
pathophysiological changes, such as an in-
creased volume of distribution and/or increased 
clearance, may occur in critically ill patients, 
and may impact on antibiotic distribution and 
concentration, resulting in slow and possible 
incomplete penetration into infected tissues 
(Scaglione, 2011). For this reason, the dosage 
of tigecycline may not be adequate in some pa-
tients and there is a high probability that the 
dosing affects mortality, at least in critically ill 
patients (Scaglione, 2011).
RE-DEFINING TIGECYCLINE THERAPY 
TREATMENT
Re-defining tigecycline therapy is needed to 
correctly understand the effects of tigecycline 
alone or in combination treatment, based on 
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epidemiological, pharmacological and clinical 
characteristics. Monotherapy may be used in 
official indications in patients with CA infec-
tions and selected patients with HCA infec-
tions, whilst HD combination therapy is given 
in a variety of patients with nosocomial and 
health-care associated infections, as prima-
ry or salvage treatment, also as a carbapen-
em-sparing strategy (Figure 1). Accordingly, 
data from patients treated with monotherapy 
or combination therapy should be analysed 
separately.
The examples for this suggestion come from the 
official studies in patients with SSTIs and IAIs, 
clinical experience, as well as from a consensus 
paper, mostly in patients with IAIs (Sartelli et 
al., 2011). The use of tigecycline in IAIs is par-
ticularly attractive in view of its PK/PD proper-
ties and its favourable in vitro activity against 
several ESBL-producing Enterobacteriaceae 
and carbapenemase-producing Enterobacte-
riaceae, Acinetobacter spp., Stenotrophomonas 
maltophilia, anaerobic bacteria and Enterococ-
ci. The IDSA guidelines for IAIs, published in 
2010, suggested the use of tigecycline for adult 
patients with mild-to-moderate community ac-
quired infections as single-agent therapy (evi-
dence level A-I) (Solomkin et al., 2010). Even if 
tigecycline has in vitro activity against MRSA 
there are few published data regarding micro-
biological and clinical efficacy in the treatment 
of patients with IAIs, and vancomycin should 
remain the first-line agent (Solomkin et al., 
2010). 
A very good assessment of tigecycline use was 
recently published by the World Society of 
Emergency Surgery (WSES) in the setting of cI-
AIs (Sartelli et al., 2011). According to the Con-
sensus, the decision tree for the antimicrobial 
management of IAIs mainly depends on three 
factors: presumed pathogens involved and risk 
factors for major resistance patterns; severity 
of disease; presumed/identified source of in-
fection. Since the major pathogens involved 
in community-acquired IAIs are Enterobacte-
riaceae, Streptococcus spp and anaerobes (es-
pecially B. fragilis), while Enterococci are fre-
quently responsible for hospital-acquired cIAIs, 
tigecycline monotherapy was recommended 
for community-acquired biliary and extrabili-
ary cIAIs in patients not critically ill with risk 
factors for ESBL, whereas tigecycline combina-
tion therapy was recommended in the follow-
ing situations: 
• Antimicrobial therapy for community-ac-
quired biliary cIAIs in critically ill patients 
(severe sepsis), in the presence of risk factors 
for ESBL (plus piperacillin ± fluconazole);
• Antimicrobial therapy for hospital-acquired 
cIAIs in non-critically ill patients (no severe 
sepsis) and risk factors for MDR pathogens 
(plus piperacillin and fluconazole);
• Antimicrobial therapy for hospital-acquired 
cIAIs in critically ill patients (± severe sepsis) 
and risk factors for MDR pathogens (plus pip-
eracillin and an echinocandin).
In patients with cSSTIs, a recent consensus 
of the Italian Society of Infectious diseases 
suggested tigecycline for the treatment of in-
fections due to MRSA (evidence level AI), es-
pecially cellulitis due to HA-MRSA, and for 
surgical site infections (Esposito et al., 2011). 
FIGURE 1 - Re-defining tigecycline 
dividing into monotherapy and com-
bination treatment. Abbreviations: 
CA = community-acquired; HCA = 
health-care associated; cSSSI = com-
plicated skin and skin structure In-
fections; MDR = multi-drug resistant. 
*The dosage of tigecycline requires 
careful microbiological, clinical and 
pharmacological considerations.
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In contrast with these recommendations, the 
2014 IDSA guidelines did not mention tigecy-
cline for cSSTIs, (Esposito et al., 2009; Stevens 
et al., 2014) probably because of the warnings 
published. 
THE ECOLOGICAL POINT OF VIEW
Tigecycline has a very wide spectrum of activ-
ity, a new mechanism of action and does not 
stimulate cross-resistance to other classes of 
antibiotics. From an ecologic point of view, car-
bapenemase-producing bacteria are increasing 
at alarming rates and proactive strategies have 
not successfully been implemented (Canton et 
al., 2012; Rocchetti et al., 2014). There are very 
few therapeutic options against KPC-Kp and 
other MDR Enterobacteriaceae. Carbapene-
mase production is normally associated with 
resistance to all β-lactams and these strains 
usually also harbor mechanisms of resistance 
to other classes of antimicrobials. No less dis-
turbing is that extended-spectrum β-lactamase 
(ESBL) production combined with alterations 
in porin expression in K. pneumoniae and 
VIM-1-producing Enterobacter cloacae may be 
the cause of treatment failure or breakthrough 
bacteraemia during therapy with carbapenems, 
despite apparent in vitro susceptibility. 
Therefore, implementation of infection control 
measures has become of major importance for 
controlling the spread of carbapenem-resistant 
Enterobacteriaceae (CRE) (Tacconelli et al., 
2014). In this scenario, due to the its unique 
mechanism of action and to the lack of induc-
tion of resistance to other antibiotic classes, 
tigecycline, alone or in combination with an-
ti-pseudomonal agents, can be an alternative to 
carbapenems because it may reduce the selec-
tion pressure for nosocomial pathogens (Liver-
more, 2005). 
Hirsch et al. reviewed a total of 15 papers in-
volving 55 unique patient cases. Agents with 
consistent in vitro activity against isolates har-
boring KPC-Kp included tigecycline and the 
tetracyclines, the polymyxins and the amino-
glycosides. From a clinical point of view, tigecy-
cline and the aminoglycosides were associated 
with positive outcomes in the majority of cases 
(Hirsch et al., 2010).
A very good example of carbapenem-sparing 
strategy, using tigecycline plus gentamicin 
or colistin, was recently published in Italy by 
Sbrana et al. (2013) who reported the effec-
tiveness (92% favorable response; 14% 30-day 
crude mortality rate) in 22 polytrauma ICU 
patients with different KPC-Kp infectious epi-
sodes (Sbrana et al., 2013).
CONCLUSION
Tigecycline is characterized by a unique mech-
anism of action and a broad spectrum of activ-
ity, including MDR pathogens, and is not asso-
ciated with cross-resistance. For these reasons, 
tigecycline has been used in a variety of CA, 
HCA and HA infections with variable severity 
and different dosages. We propose a re-defini-
tion to separately analyse tigecycline monother-
apy and HD combination treatment because of 
different epidemiological, microbiological and 
clinical characteristics.
Whilst available clinical data suggest strong 
caution with monotherapy in severe infections, 
monotherapy may be safe in the official indi-
cations, although individual pharmacological 
characteristics need to be considered as far as 
the dosage is concerned. A combination treat-
ment with HD tigecycline may be appropriate 
in patients with a variety of HCA and HA in-
fections, especially cIAIs, possibly due to MDR 
Gram-negative or carbapenemase-producing 
bacteria, but also as part of a carbapenem-spar-
ing strategy, as a primary empiric or targeted 
treatment and even as a de-escalation.
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